Drug
Pegylated Interferon-alpha (IFN)
Pegylated Interferon-alpha (IFN) is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Phase Distribution
Ph phase_2
1
33%
Ph not_applicable
1
33%
Ph phase_3
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (33.3%)
Phase 31 (33.3%)
N/A1 (33.3%)
Trials by Status
completed267%
not_yet_recruiting133%
Recent Activity
0 active trials
Showing 3 of 3
not_yet_recruitingnot_applicable
Sequential PEG-IFN for HBV After Ending RNA-targeted Regimens
NCT06923280
completedphase_3
Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)
NCT01358864
completedphase_2
Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)
NCT00984620
Clinical Trials (3)
Showing 3 of 3 trials
NCT06923280Not Applicable
Sequential PEG-IFN for HBV After Ending RNA-targeted Regimens
NCT01358864Phase 3
Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)
NCT00984620Phase 2
Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3